Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Guatemala: These 4 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Guatemala: These 4 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Guatemala?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Guatemala Patent 200,900,302

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Guatemala?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Guatemala Patent 200,900,314

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Guatemala?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Guatemala Patent 201,000,144
Patent Title: " COMPOSICIONES FARMACEUTICAS "

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Guatemala?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Guatemala Patent 201,000,182

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

Guatemala Branded and Generic Drug Market Assessment, Regulation, and Investment Opportunities

Last updated: October 15, 2026

Guatemala is Central America's largest pharmaceutical market by population and one of the region's most commercially important destinations for branded, generic, over-the-counter, and hospital medicines. The market is fragmented between private pharmacies, wholesalers, hospitals, public procurement, and social-security purchasing. Branded products retain strength in high-income and specialist segments, while generics compete on price in primary care and institutional tenders. The main commercial constraints are registration delays, public-procurement volatility, weak payment discipline, fragmented distribution, and limited enforcement capacity. The principal regulatory opportunities are local registration services, generic substitution, contract manufacturing, cold-chain distribution, specialty medicines, and participation in public tenders.

What is the structure of Guatemala's pharmaceutical market?

Guatemala has a mixed market with a large private channel and a public sector that purchases medicines through centralized and decentralized mechanisms.

Segment Market characteristics Commercial implications
Private retail Pharmacy chains, independent pharmacies, physician prescribing, self-medication Strongest channel for branded generics, OTC products, and chronic therapies
Private hospitals and clinics Imported medicines and specialist products Opportunity for oncology, biologics, injectables, anesthesia, and hospital products
Ministry of Public Health and Social Assistance Public hospitals, health centers, tenders, framework purchasing High volume but price-sensitive and administratively demanding
Guatemalan Social Security Institute Institutional procurement for insured patients Attractive for chronic disease and specialty products; tender access is essential
Wholesalers and distributors Importation, warehousing, national delivery Critical route to market for foreign manufacturers without a local entity
Informal and semi-formal trade Risk of unregistered, diverted, or counterfeit products Creates price pressure and compliance exposure

Guatemala has a population of roughly 18 million and the largest population base in Central America. Demand is supported by population growth, urbanization, chronic disease, private healthcare spending, and limited public access to medicines. The market remains less concentrated than the major pharmaceutical markets of Mexico, Brazil, or Colombia.

Publicly available sources do not provide a single authoritative annual market value covering all branded and generic medicine sales. Commercial estimates differ according to whether they include OTC products, hospital medicines, institutional tenders, and parallel trade. Market analysis should therefore use channel-specific sales data rather than a single headline market figure.

Which therapeutic areas drive demand in Guatemala?

Demand is divided between acute-care products and expanding chronic-care categories.

High-demand therapeutic categories

  • Cardiovascular medicines, including antihypertensives and lipid-lowering agents
  • Diabetes treatments, including insulin and oral antidiabetic drugs
  • Respiratory medicines, including inhaled products and allergy therapies
  • Anti-infectives and antimicrobial products
  • Gastrointestinal medicines
  • Analgesics and anti-inflammatory drugs
  • Women’s health and reproductive-health products
  • Pediatric medicines
  • Oncology and specialty hospital medicines
  • Vitamins, nutritional products, and OTC products

The branded market is strongest where physicians influence product selection, treatment complexity is high, or patients associate brand identity with quality. Generic penetration is higher for established molecules with multiple suppliers, particularly in primary care and public procurement.

Biologics and biosimilars remain smaller than conventional small-molecule medicines but offer higher-value growth opportunities. Their commercial success depends on procurement specifications, interchangeability policy, pharmacovigilance, cold-chain capability, and physician confidence.

How does Guatemala regulate branded and generic drugs?

The principal regulator is the Ministry of Public Health and Social Assistance, through the Department of Regulation and Control of Pharmaceutical and Related Products, commonly referred to as DRCPFA.

The core legal framework includes:

Regulatory area Principal framework
Public-health authority Guatemala Ministry of Public Health and Social Assistance
Product registration Regulation for the Control of Medicines and Related Products, Government Agreement 712-99
Health code Decree 90-97, Código de Salud
Intellectual property Industrial Property Law, Decree 57-2000
Regional technical standards Central American Technical Regulations, or RTCA
International trade and IP CAFTA-DR and WTO obligations
Controlled substances National controlled-substance requirements and applicable international conventions

A product generally requires sanitary registration before importation, distribution, or sale. The dossier normally includes administrative information, labeling, manufacturing information, quality data, stability information, and, where required, safety and efficacy documentation.

Guatemala uses Central American technical standards in areas such as pharmaceutical registration, labeling, good manufacturing practices, stability, bioequivalence, and pharmacovigilance. Requirements can change through regional harmonization, but implementation and administrative practice remain country-specific.

What is the drug registration process in Guatemala?

The registration process is document-intensive and depends heavily on dossier quality and local regulatory execution.

Typical steps include:

  1. Appointment of a local legal representative or authorized applicant.
  2. Preparation of the technical and administrative dossier.
  3. Submission to DRCPFA.
  4. Regulatory review and issuance of deficiency notices where applicable.
  5. Payment of applicable government fees.
  6. Approval or rejection of the application.
  7. Import licensing and customs compliance.
  8. Post-approval maintenance, renewals, variations, and pharmacovigilance.

Common submission problems include inconsistent manufacturer names, incomplete certificates of pharmaceutical product, unsuitable stability data, inadequate Spanish labeling, missing legalized documents, and discrepancies between the registration dossier and commercial packaging.

Foreign manufacturers usually need a competent local partner for regulatory representation, importation, distribution, and post-market compliance. A local distributor can accelerate market access but may reduce control over pricing, customer relationships, tender strategy, and pharmacovigilance.

When does Guatemala grant market exclusivity for new medicines?

Guatemala does not operate an FDA-style Orange Book system or a publicly equivalent national listing that consolidates all pharmaceutical patent and exclusivity information.

Patent protection is generally available for 20 years from the filing date under the Industrial Property Law, subject to statutory requirements and applicable treaty obligations. Patent rights normally cover the claimed invention, which may include:

  • Active pharmaceutical ingredients
  • Polymorphs and salts
  • Formulations
  • Dosage forms
  • Manufacturing processes
  • Combinations
  • Methods of treatment, where legally protectable under the applicable framework
  • Drug-delivery systems

CAFTA-DR requires protection of undisclosed test data for certain new pharmaceutical products. The agreement establishes a five-year period for new chemical entities in relevant circumstances, subject to the treaty and implementing rules. The practical scope depends on whether the product qualifies as a new chemical entity, whether prior regulatory approval exists in another market, and how the Guatemalan authorities apply the relevant rules.

Data protection and patent protection are separate. A product may have no remaining patent but still face a regulatory barrier based on protected clinical or test data. Conversely, regulatory data protection may expire while formulation or process patents remain enforceable.

What patents protect medicines in Guatemala?

Patent risk must be assessed through the Guatemalan Intellectual Property Registry and international patent-family analysis. Foreign patent numbers do not automatically establish enforceability in Guatemala. A US, European, or PCT publication may identify relevant rights but does not substitute for a Guatemalan national-stage filing or locally enforceable right.

A due-diligence review should identify:

Patent issue Key question
Composition patent Does a granted Guatemalan patent cover the active ingredient?
Formulation patent Does the generic use the same excipient system, release profile, or dosage form?
Process patent Does manufacturing practice fall within a claimed process?
Method-of-use patent Does the proposed label include the patented indication?
Patent term Has the 20-year term expired or been adjusted?
Ownership Has the patent been assigned or licensed?
Maintenance Are required fees current?
Enforcement Is there an injunction, infringement action, or settlement?

There is no publicly comparable Orange Book mechanism for routine patent certification. Generic manufacturers must conduct independent freedom-to-operate analysis and avoid reliance on US Paragraph IV conclusions.

Are Paragraph IV challenges available in Guatemala?

Guatemala does not use the US Hatch-Waxman Paragraph IV system. A generic applicant does not file a US-style certification asserting that a listed patent is invalid or will not be infringed.

A generic launch can still create patent litigation risk through:

  • Civil infringement proceedings
  • Requests for provisional measures
  • Customs or border actions where available
  • Unfair-competition claims
  • Regulatory or commercial disputes over labeling and indications
  • Contract disputes involving distributors or licensees

The absence of a formal Paragraph IV route reduces procedural predictability for early generic challenges. It does not eliminate patent risk. Companies must separate regulatory approval timing from lawful commercialization timing.

What is the Orange Book status of medicines in Guatemala?

Guatemala has no US Orange Book equivalent. The US FDA Orange Book may provide useful information about US patents and exclusivity for comparison, but those listings do not determine Guatemalan rights.

Market participants should maintain a product-level register containing:

  • Guatemalan patent applications and grants
  • Patent-family members
  • Filing and grant dates
  • Expected expiration
  • Patent annuity status
  • Regulatory data-protection period
  • Sanitary-registration status
  • Approved indications
  • Local marketing authorization holder
  • Litigation and settlement history

This register is more useful than applying US patent assumptions directly to Guatemala.

What regulatory opportunities exist for generic drug companies?

The strongest generic opportunities are in high-volume, off-patent molecules with multiple prescribers and established demand.

Commercial opportunities

Branded generics. Physician and pharmacy acceptance can support branded generics where quality assurance, supply reliability, and local promotion are stronger than low-price competitors.

Institutional tenders. Public and social-security tenders can generate substantial volume. The risks are low margins, technical disqualification, delayed awards, and payment delays.

Chronic disease medicines. Hypertension, diabetes, asthma, and gastrointestinal products offer recurring demand and opportunities for portfolio expansion.

OTC products. Analgesics, antacids, cough and cold products, vitamins, and dermatology products can achieve broad pharmacy distribution with comparatively lower prescribing barriers.

Specialty generics. Oncology, injectables, hospital anti-infectives, and critical-care medicines can offer higher margins but require stronger quality systems and supply continuity.

Local packaging and manufacturing. Local secondary packaging, labeling, and selected manufacturing operations can improve tender eligibility and reduce logistics costs. It also creates additional GMP and inspection obligations.

What challenges affect branded drug companies?

Branded companies face competition from low-cost generics, purchasing fragmentation, currency exposure, distributor dependence, and variable enforcement.

The principal risks are:

  • Price erosion after loss of patent or data exclusivity
  • Product substitution at the pharmacy level
  • Unregistered or counterfeit products
  • Weak control over distributor inventory
  • Tender losses based on price
  • Import delays and customs documentation errors
  • Pharmacovigilance obligations without adequate local infrastructure
  • Unclear separation between promotional activity and improper inducement
  • Limited public reimbursement
  • Delayed government payments
  • Parallel import or diversion concerns

Premium pricing is most defensible when a product has a differentiated delivery system, strong clinical evidence, reliable availability, specialist demand, or a protected indication.

How strong is Guatemala's pharmaceutical patent and regulatory protection?

Guatemala provides a treaty-based IP framework, but enforcement and administrative predictability are more important commercial variables than statutory rights alone.

Factor Assessment
Patent term Generally 20 years from filing
Regulatory data protection Five-year CAFTA-DR framework for qualifying new pharmaceutical products
Orange Book Not available as a national system
Paragraph IV pathway Not available
Generic approval Available after applicable regulatory requirements are met
Local representation Generally required for regulatory and commercial operations
Enforcement Available but timing and practical effectiveness can vary
Regional harmonization Meaningful through RTCA, with country-level implementation
Biosimilar framework Developing and requiring product-specific regulatory review
Procurement risk High price sensitivity and administrative variability

The estate of a branded product is stronger when it combines an active ingredient patent with formulation, process, delivery, or indication claims and maintains a reliable regulatory and commercial record. A single expired compound patent provides limited protection against well-prepared generic entry.

What biosimilar risks exist in Guatemala?

Biosimilar competition is less mature than small-molecule generic competition but is likely to expand as biologic spending increases and public purchasers seek lower-cost alternatives.

Key issues include:

  • Product-specific comparability requirements
  • Reference-product selection
  • Immunogenicity data
  • Pharmacovigilance
  • Interchangeability and substitution
  • Cold-chain control
  • Naming and traceability
  • Tender specifications
  • Physician acceptance

Biologic manufacturers should not assume that approval of a biosimilar automatically creates pharmacy-level substitution. Substitution rules, procurement terms, institutional protocols, and medical practice may determine actual switching behavior.

What litigation and settlement risks affect drug launches?

Drug litigation data in Guatemala is less transparent than in the United States. There is no centralized public database that reliably captures every pharmaceutical patent dispute, regulatory challenge, settlement, and provisional measure.

Launch planning should examine:

  • Local patent-register searches
  • Court and customs records where available
  • Distributor representations and warranties
  • Patent-owner cease-and-desist activity
  • Global litigation involving the same product family
  • Local regulatory decisions
  • Settlement restrictions in related jurisdictions
  • Supply and licensing agreements

A settlement negotiated in the United States or Europe does not automatically bind Guatemala. Its commercial effect depends on the parties, territorial scope, contractual language, and locally enforceable rights.

How does Guatemala compare with other Central American markets?

Guatemala is attractive because of its population, private healthcare demand, commercial centrality, and role as a distribution base. It is also more operationally complex than a simple export market.

Market factor Guatemala Regional implication
Population base Largest in Central America Supports broader product portfolios
Private pharmacy channel Important and fragmented Requires local distribution capability
Public procurement Material but price-sensitive Volume opportunity with payment risk
Regulatory harmonization Uses RTCA standards Can reduce dossier duplication
Patent system Treaty-based, country-specific Requires local freedom-to-operate review
Market access Local representative and registration required Foreign companies need in-country execution
Distribution role Regional commercial hub Potential base for Central American expansion

Regional harmonization can reduce technical duplication but does not eliminate country-level regulatory, language, import, pricing, tender, or enforcement differences.

What is the recommended market-entry strategy?

A practical entry model is a staged launch:

  1. Select molecules with clear freedom to operate, stable demand, and limited patent exposure.
  2. Appoint a local regulatory representative with proven DRCPFA experience.
  3. Use a distributor with pharmacy, hospital, and tender capabilities rather than relying on a purely retail-focused partner.
  4. Submit Spanish-compliant dossiers with harmonized certificates and consistent manufacturer data.
  5. Establish a local pharmacovigilance process before launch.
  6. Separate private-channel pricing from institutional tender pricing.
  7. Protect trademarks and local commercial contracts.
  8. Monitor sanitary registrations, patent rights, tenders, and distributor performance.
  9. Expand into specialty generics only after quality, supply, and cold-chain controls are established.
  10. Review regional expansion into El Salvador, Honduras, Nicaragua, Costa Rica, and the Dominican Republic separately.

Key Takeaways

  • Guatemala is Central America's largest pharmaceutical opportunity by population and a significant regional distribution market.
  • Branded medicines remain competitive in specialist and premium segments, while generics dominate price-sensitive and institutional purchasing.
  • DRCPFA is the principal pharmaceutical regulator, operating under Guatemala's health laws and Central American technical regulations.
  • Guatemala does not have a national Orange Book or a US-style Paragraph IV system.
  • Pharmaceutical patents generally run for 20 years from filing, while qualifying new chemical entities may receive five years of regulatory data protection under CAFTA-DR.
  • Generic launch risk depends on local patent status, data protection, labeling, procurement, and distributor execution.
  • The strongest opportunities are branded generics, chronic-care products, OTC medicines, specialty generics, hospital products, and regulatory services.
  • The main risks are registration delays, fragmented distribution, public-tender pricing, payment delays, weak enforcement, and limited transparency on litigation.
  • Biosimilar competition is developing and will depend heavily on procurement, interchangeability, pharmacovigilance, and cold-chain capability.

FAQs About Guatemala's Branded and Generic Drug Market

Does Guatemala require local clinical trials for generic medicines?

Not routinely. Generic applications generally rely on quality, pharmaceutical equivalence, bioequivalence where required, and supporting regulatory documentation. Product-specific requirements depend on the active ingredient, dosage form, therapeutic category, and applicable RTCA standards.

Can a foreign pharmaceutical company sell directly in Guatemala?

A foreign company normally needs a local regulatory and commercial structure for sanitary registration, importation, distribution, and post-market obligations. Direct selling without an appropriate local arrangement creates regulatory and operational risk.

Are generic medicines automatically substituted for branded medicines in Guatemala?

No automatic assumption should be made. Actual substitution depends on regulatory rules, pharmacy practice, prescriber behavior, institutional procurement terms, and the product category.

How long does pharmaceutical registration take in Guatemala?

Timing varies by product, dossier quality, authority workload, deficiency notices, and document legalization. A fixed approval period should not be assumed for commercial planning.

Does a Guatemalan patent block Central American generic sales?

No. Patent rights are territorial. A Guatemalan patent affects Guatemala, while sales in other Central American countries require separate country-level patent and regulatory analysis.

References

  1. Central American Integration System. (n.d.). Central American Technical Regulations for medicines and pharmaceutical products. https://www.sica.int/

  2. Congreso de la República de Guatemala. (1997). Decreto Número 90-97: Código de Salud.

  3. Congreso de la República de Guatemala. (2000). Decreto Número 57-2000: Ley de Propiedad Industrial.

  4. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugsatfda

  5. Ministry of Public Health and Social Assistance of Guatemala. (1999). Acuerdo Gubernativo Número 712-99: Reglamento para el Control Sanitario de los Medicamentos y Productos Afines.

  6. Office of the United States Trade Representative. (2004). Dominican Republic-Central America-United States Free Trade Agreement. https://ustr.gov/

  7. World Trade Organization. (1994). Agreement on trade-related aspects of intellectual property rights. https://www.wto.org/

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.